enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Biosimilar - Wikipedia

    en.wikipedia.org/wiki/Biosimilar

    The first biosimilar of a monoclonal antibody to be approved worldwide was a biosimilar of infliximab in the EU in 2013. [9] On March 6, 2015, the FDA approved the United States' first biosimilar product, the biosimilar of filgrastim called filgrastim-sndz (trade name Zarxio) by Sandoz.

  3. Teva CEO says not too late to launch Humira biosimilar in 2024

    www.aol.com/news/teva-ceo-says-not-too-162604893...

    Eight companies have launched Humira biosimilars in the United States this year. ... -Teva Pharmaceutical Industries will still pursue launching a biosimilar of AbbVie's blockbuster arthritis drug ...

  4. Novartis' Sandoz targets biosimilar version of J&J drug in ...

    www.aol.com/news/novartis-sandoz-targets...

    Samsung Bioepis' clinical development programme for the Stelara biosimilar is well-advanced and Sandoz secured the rights to commercialize the product in the United States, Canada and most of ...

  5. FDA Approves Biosimilars for Macular Degeneration Treatment - AOL

    www.aol.com/fda-approves-biosimilars-macular...

    Yesafili is already approved as a biosimilar in Europe and the United Kingdom, and is approved in Canada and is expected to launch there by July 2025, Biocon Biologics said in a press release.

  6. Specialty drugs in the United States - Wikipedia

    en.wikipedia.org/wiki/Specialty_drugs_in_the...

    By 2011 in the United States a growing number of Medicare Part D health insurance plans—which normally include generic, preferred, and non-preferred tiers with an accompanying rate of cost-sharing or co-payment—had added an "additional tier for high-cost drugs which is referred to as a specialty tier". [42]: 1

  7. Biologics Price Competition and Innovation Act of 2009

    en.wikipedia.org/wiki/Biologics_Price...

    The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) amends the Public Health Service Act (PHS Act) to create an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product.

  8. Novartis' Sandoz wagers its standalone future on biosimilar ...

    www.aol.com/news/novartis-sees-sandoz-adding-3...

    Novartis' soon-to-be spun off generics division Sandoz is betting on biosimilars, copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer, to fuel its future as ...

  9. Adalimumab - Wikipedia

    en.wikipedia.org/wiki/Adalimumab

    Adalimumab was approved for medical use in the United States in 2002. [44] [47] It is on the World Health Organization's List of Essential Medicines. [48] It is available as a biosimilar medication. [49] In 2022, it was the 241st most commonly prescribed medication in the United States, with more than 1 million prescriptions. [50] [51]